Management of late urinary side effects after pelvic radiation therapy: a scoping review
Clinical and Translational Radiation Oncology · 2027-01 · 62 · 101332
DOI: 10.1016/j.ctro.2026.101332 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Radiation Oncology, 2027-01. Verfasst von Laura Mullaney und 1 weiteren Autor:innen. Beteiligte Einrichtung: Applied Radiation Therapy Trinity (ARTT), Discipline of Radiation Therapy, School of Medicine, Trinity St. James's Cancer Institute, Trinity College …. Die Arbeit nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Radiation therapy (RT) is a cornerstone treatment for pelvic malignancies but can cause durable urinary side effects that impair quality of life. Presentations range from haematuria and irritative symptoms to stricture, fistula, osteomyelitis, and end-stage urinary failure. This scoping review maps the management strategies for late urinary side effects after pelvic RT.
Methods
A PRISMA-ScR-guided search of PubMed and Embase identified studies published from January 2015 to April 2026. Primary studies reporting management outcomes were included. Two reviewers assessed full-text eligibility. Data were charted by syndrome, intervention, design, population, RT characteristics, follow-up and outcomes. Risk of bias in randomised trials was assessed using RoB.
Results
69 studies of previously irradiated patients were included, predominantly retrospective cohorts. RT modality was reported in 56% of publications, total dose in 33%, and the interval from RT to toxicity in 70%. Hyperbaric oxygen therapy (HBOT) had the strongest evidence for radiation cystitis, supported by randomised data and long-term follow-up. Reconstructive surgery for urethral and ureteral strictures achieved acceptable patency, but recurrence and incontinence remained common. Fistula, osteomyelitis, and refractory bleeding were often managed with salvage diversion in severe or refractory cases, which reduced pain and treatment burden despite substantial perioperative morbidity.
Conclusions
Evidence is strongest for HBOT in chronic radiation cystitis. Elsewhere, management rests on retrospective, expert-centre series. Clinical decision-making is best guided by syndrome, severity, and tissue quality, treating prior RT modality and dose as markers of injury burden, with timely referral and shared decision-making when repeated intervention fails to provide durable control.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Applied Radiation Therapy Trinity (ARTT), Discipline of Radiation Therapy, School of Medicine, Trinity St. James's Cancer Institute, Trinity College Dublin, University of Dublin, Dublin, Ireland.
Zitieren
APA
Mullaney, L., & Bennani, S. (2027). Management of late urinary side effects after pelvic radiation therapy: a scoping review. Clinical and Translational Radiation Oncology, 62, 101332. https://doi.org/10.1016/j.ctro.2026.101332
Vancouver
Mullaney L, Bennani S. Management of late urinary side effects after pelvic radiation therapy: a scoping review. Clinical and Translational Radiation Oncology. 2027;62:101332. doi:10.1016/j.ctro.2026.101332
BibTeX
@article{Mullaney2027,
author = {Mullaney, Laura and Bennani, Salma},
title = {Management of late urinary side effects after pelvic radiation therapy: a scoping review},
journal = {Clinical and Translational Radiation Oncology},
year = {2027},
volume = {62},
pages = {101332},
doi = {10.1016/j.ctro.2026.101332}
}
EUVIMED